University of Chicago
The purpose of this study is to characterize the pharmacokinetics of one or more ICIs during and after TPE/PLEX in patients with severe irAEs.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy across multiple tumor types; however, their mechanism of action-releasing immune inhibition-inevitably predisposes patients to immune-related adverse events (irAEs). These toxicities occur in up to 74% of patients treated with PD-(L)1 inhibitors and in more than 90% of those receiving combination therapy, with grade 3-5 events in 14-55% of cases depending on regimen and tumor type. Immune-related adverse events caused by ICIs often present with a spectrum of clinical manifestations that closely resemble primary autoimmune d…
Inclusion Criteria: * Adults ≥ 18 years of age * Diagnosis of any malignancy. * Receiving or recently received an immune checkpoint inhibitor, including anti-PD-1, anti-PD-L1, anti-CTLA-4, or combination ICI therapy. Eligible agents may include, but are not limited to, pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, cemiplimab, dostarlimab, and ipilimumab. * Received an ICI within 12 weeks prior to planned enrollment, or within a timeframe considered appropriate by the PI for PK evaluation based on the specific ICI agent, dosing history, and assay feasibility. * Suspected or con…
Therapeutic plasma exchange (using the Spectra Optia Apheresis System) will be done according to standard of care.
Arctuva estimate
Verify or correct the compensation shown for this listing.